The new ID-heparin/PF4: antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays

被引:74
作者
Eichler, P
Raschke, R
Lubenow, N
Meyer, O
Schwind, P
Greinacher, A
机构
[1] Univ Greifswald, Inst Immunol & Transfus Med, D-17487 Greifswald, Germany
[2] Humboldt Univ, Blood Bank, Charite Campus Virchow Clin, Berlin, Germany
[3] DiaMed SA, Cressier Sur Morat, Switzerland
关键词
heparin-induced thrombocytopenia; HIT; antibodies; laboratory diagnosis;
D O I
10.1046/j.0007-1048.2002.03363.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication of heparin treatment. Several in vitro assays are available to detect the causative fur antibodies: functional assays, usually requiring freshly prepared platelets and immunological tests based on the enzyme-linked immunosorbent assay (ELISA) principle. We compared a new, simple and rapid test based on the ID-microtyping particle agglutination system with 14C-serotonin release assay, heparin-induced platelet activation (HEPA) test and two EIASAs. Sera from 100 confirmed HIT patients, 20 serologically negative suspected HIT patients and 20 healthy blood donors were used. The specificity and sensitivity of the new test was similar to the functional assays. Compared with the ELISAs, specificity was better at the cost of reduced sensitivity. As in all other immunological tests, HIT antibodies against less typical antigens, such as interleukin (IL)-8 or neutrophil-activating peptide (NAP) 2 could not be detected. Thus, although the ID-Heparin/PF4 antibody test seems to be a quick, reliable and robust test to determine the presence of HIT antibodies, it should still be combined with a functional assay if possible. Evaluation of the test in a prospective setting as well as interlaboratory variation should be assessed as a next step.
引用
收藏
页码:887 / 891
页数:5
相关论文
共 24 条
[1]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[2]   Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia [J].
Amiral, J ;
MarfaingKoka, A ;
Wolf, M ;
Alessi, MC ;
Tardy, B ;
BoyerNeumann, C ;
Vissac, AM ;
Fressinaud, E ;
Poncz, M ;
Meyer, D .
BLOOD, 1996, 88 (02) :410-416
[3]  
AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21
[4]   HEPARIN-INDUCED THROMBOCYTOPENIA - MECHANISM OF INTERACTION OF THE HEPARIN-DEPENDENT ANTIBODY WITH PLATELETS [J].
CHONG, BH ;
FAWAZ, I ;
CHESTERMAN, CN ;
BERNDT, MC .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (02) :235-240
[5]   IMMUNE ENDOTHELIAL-CELL INJURY IN HEPARIN-ASSOCIATED THROMBOCYTOPENIA [J].
CINES, DB ;
TOMASKI, A ;
TANNENBAUM, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (10) :581-589
[6]  
CINES DB, 1989, REV INFECT DIS, V11, P705
[7]  
Eichler P, 1999, THROMB HAEMOSTASIS, V81, P625
[8]  
FRATANTONI JC, 1975, BLOOD, V45, P395
[9]   Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range [J].
Greinacher, A ;
Eichler, P ;
Lubenow, N ;
Kwasny, H ;
Luz, M .
BLOOD, 2000, 96 (03) :846-851
[10]  
GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247